The Clinical Development of Thalidomide as an Angiogenesis Inhibitor Therapy for Prostate Cancer
Annual rept. 28 Sep 2001-27 Sep 2002
MD ANDERSON CANCER CENTER SMITHVILLE TXSCIENCE PARK RESEARCH DIV
Pagination or Media Count:
The purpose of this award is to evaluate the 1 Safety and toxicity of neo-adjuvant thalidomide therapy prior to radical prostatectomy in patients with locally advanced prostate carcinoma PCa, assessed by wound healing and peri-operative bleeding 2 Efficacy of neo-adjuvant thalidomide treatment, as measured by the rate of tumor reduction I PSA decline while on thalidomide therapy 3 Qualitative measurements of the in vivo effect of thalidomide therapy on the Endothelial and Epithelial compartment PCa cells.
- Medicine and Medical Research